Meiji Seika Pharma said on April 24 that it has snagged Taiwanese regulatory approval for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (cGVHD). The drug is expected to be rolled out in October-December through its local subsidiary.Rezurock is…
To read the full story
Related Article
- Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
- Meiji’s Rezurock Approved in Thailand
August 25, 2025
BUSINESS
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Teikoku, Curedisc Ink Japan Deal for Disc Herniation Drug
April 28, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





